Reno、NVにおける乳がんの臨床試験
Renoとその周辺地域（約30マイル以内）の拠点で、乳がんに関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Cancer Care Specialists, Reno
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Carson Tahoe Regional Medical Center, Carson City · 25マイル先
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- Cancer Care Specialists, Reno
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- Renown Regional Medical Center ( Site 0041), Reno
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
被験者募集中第1/2相
- Renown Regional Medical Center, Reno
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
被験者募集中第3相
- Research Site, Reno
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Renown Health Medical Oncology, Reno
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
被験者募集中観察研究
- Cancer Care Specialist of Reno, Reno
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24マイル先
- 他1件
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24マイル先
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
被験者募集中第3相
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Renown Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24マイル先
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- Renown Regional Medical Center, Reno
他の都市における乳がんの試験
- New York City, NY134件の研究
- Houston, TX126件の研究
- Boston, MA111件の研究
- Nashville, TN80件の研究
- Los Angeles, CA72件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Durham, NC63件の研究
- Queens, NY63件の研究
- Chicago, IL58件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Renoにおける他の研究
- 非小細胞肺癌16件の研究
- 肺がん9件の研究
- 黄斑変性症8件の研究
- 地図状萎縮8件の研究
- 卵巣がん7件の研究
- がん（全種類）7件の研究
- 大腸癌5件の研究
- 急性骨髄性白血病5件の研究
- 転移性癌5件の研究
- 膵臓がん5件の研究
- 結腸癌5件の研究
- 直腸がん4件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。